Testing benefits and side effects of hormone therapy in older breast cancer patients
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older
- Your breast cancer is estrogen and/or progesterone receptor–positive and HER2-negative
- Your tumor size and grade meet specific limits (smaller for higher grades)
- Your cancer has been treated with surgery plus appropriate radiation (if you had breast-conserving surgery) or surgery alone after mastectomy
- There are no cancer cells in the armpit lymph nodes (node-negative)
- You can understand the study and complete questionnaires in English or French
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether using hormone (endocrine) treatment alone can control breast cancer in people age 70 and older. It targets breast cancers that are estrogen-receptor positive and HER2 negative, aiming to avoid chemotherapy-like treatments in suitable patients.
This study looks at how genetic tests like Oncotype DX or Mammaprint are used to guide treatment decisions for people with early-stage, hormone receptor-positive (HR+) and HER2-negative breast cancer. It aims to help doctors choose between hormone therapy alone or chemotherapy plus hormone therapy.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
This trial studies whether younger, premenopausal women with early-stage, hormone-sensitive breast cancer can safely use hormone therapy alone after surgery, based on their tumor's gene activity score (Oncotype DX). It aims to find the best treatment approach based on your cancer's biology.
This trial tests a chemotherapy-free approach for women age 65 and older with a common type of breast cancer (ER-positive, HER2-negative) that has spread to lymph nodes. Instead of chemotherapy, you would receive an oral targeted therapy (CDK4/6 inhibitor) after surgery to see if it can prevent the cancer from coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.